Global Anthelmintics Market, By Drug Class (Benzimidazoles, Piperazine), Target Pathogen (Ancylostoma Duodenale, Ascaris Lumbricoides, Enterobius Vermicularis, Trichuris Trichiura), Drugs (Miltefosine, Thiabendazole, Praziquantel, Mebendazole, Albendazole, Pyrantel, Ivermectin, Others), Application (Angiostrongylosis, Ascariasis, Capillariasis, Echinococcus, Gnathostomiasis, Liver Fluke, Moniliformis Infection, Trichostrongylosis, Enterobiasis, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
An anthelmintic is a medication that is used to treat parasitic worm infestations in animals. This comprises both flat and round worms, such as flukes (trematodes) and tapeworms (cestodes). These medications block metabolic activities that are essential to the parasite but not to the host. The intestines do not well absorb some anthelmintics. As a result, the parasite is exposed to the medicine at a far higher concentration than the host body. Neuromuscular coordination, energy production, and microtubular integrity are all important in the worm's life cycle. Antihelmintic medications are usually taken orally because this is the most stable way of administration.
Data Bridge Market Research analyses that the anthelmintics market was valued at USD 2,846.90 million in 2021 and is expected to reach USD 5,435.60 million by 2029, registering a CAGR of 8.42% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Benzimidazoles, Piperazine), Target Pathogen (Ancylostoma Duodenale, Ascaris Lumbricoides, Enterobius Vermicularis, Trichuris Trichiura), Drugs (Miltefosine, Thiabendazole, Praziquantel, Mebendazole, Albendazole, Pyrantel, Ivermectin, Others), Application (Angiostrongylosis, Ascariasis, Capillariasis, Echinococcus, Gnathostomiasis, Liver Fluke, Moniliformis Infection, Trichostrongylosis, Enterobiasis, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Amneal Pharmaceuticals LLC. (US), Mankind Pharma (India), Zydus Cadila (India), GALDERMA (Switzerland), Zoetis (US), Boehringer Ingelheim International GmbH. (Germany), Bayer AG (Germany), Merck KGaA (Germany)
|
|
Market Opportunities
|
|
Market Definition
Anthelmintics are medications that destroy helminths. Flukes, roundworms, and tapeworms are helminth parasites that look like worms. Anthelmintics must be selectively harmful to the parasite rather than the host. Some work by interfering with metabolic processes that are essential to the parasite but not to the host. Other anthelmintics are poorly absorbed via the gut, exposing the parasite to significantly higher anthelmintic concentrations than the host. The parasite is then expelled or digested after starvation or paralysis.
Anthelmintics Market Dynamics
Drivers
- Increasing prevalence of helminth infections
The rising prevalence of helminth infections caused by roundworm, whipworm, hookworm, and other worms is anticipated to drive the growth of the anthelmintics market. Various parasitic worm species cause soil-transmitted helminth infections. According to the WHO, about 1.5 billion people worldwide were infected with soil-transmitted helminths as of March 2020. Ascaris lumbricoides (roundworms), trichuris trichiura (whipworms), necator americanus, and ancylostoma duodenale are some of the major disease-causing species (hookworms). Furthermore, S. stercoralis is thought to harm roughly 600 million people worldwide. Other variables that increase the occurrence of soil-transmitted helminth infections around the world include poor hygiene and sanitation.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of anthelmintics market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Increasing number of government initiatives
Government initiatives and a paradigm change in focus toward assisting in the management of helminth infections around the world are expected to boost the market for anthelmintic medications. The National Deworming Day, for example, is a major attempt by India's Ministry of Health and Family Welfare to rid the country of worms. According to the WHO, in India, 241 million children aged 1 to 14 years are at risk of parasitic intestinal worms. As a result, the government is expected to create recommendations to raise awareness and eliminate helminth infection.
Furthermore, surging geriatric population and rise in the number of infected patients globally will result in the expansion of anthelmintics market. Along with this, favourable reimbursement policies will enhance the market's growth rate.
Opportunities
- Rise in the number of clinical trials
Organizations in the anthelmintic pharmaceuticals industry are strengthening their productivity in AI-driven drug development approaches in order to capitalize on revenue creation potential following the approval of niclosamide. Companies in the anthelmintic medicine sector are working to undertake clinical trials on current drugs that could be used to treat coronavirus.
Moreover, the market's growth is fueled by an increase in the number of research and development activities and emerging new markets. These factors will provide beneficial opportunities for the anthelmintics market growth. Along with this, growing number of strategic collaborations to find new treatments for Ascaris Lumbricoides (Roundworm) infection will create new market opportunities.
Restraints/Challenges
On the other hand, the high cost associated with the drug development distribution will obstruct the market's growth rate. Developing economies' lack of healthcare infrastructure and dearth of skilled professionals will challenge the anthelmintics market. Additionally, lack of awareness among people and side effects of drugs such as headache, vertigo, nausea, vomiting, anemia, fever, and others will restrain and further impede the market's growth rate during the forecast period of 2022-2029.
This anthelmintics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anthelmintics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Anthelmintics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Anthelmintics Market
The outbreak of COVID-19 had a major influence on the market. As workforce reductions have restricted import and export activity, there has been a significant impact on the market, resulting in anthelmintics drug shortages and unavailability in healthcare facilities. The first impact of the outbreak on the anthelmintics market was substantial due to temporary shutdowns of production facilities, export restrictions, increased demand for the COVID-19 treatment, disruptions in the supply of commodities, and service outages. According to the World Health Organization (WHO), most malaria-endemic countries saw moderate delays in anti-parasitic service delivery in 2020. In the year 2021, however, the demand for COVID-19 treatment with various medications, such as antiviral and anthelmintics, increased significantly. The effect of these medications on new coronaviruses was investigated in clinical studies.
Recent Development
- In February 2020, Zoetis had announced the U.S. Food and Drug Administration (FDA) approval for Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets), the first once-monthly, chewable tablet in the U.S. This medication delivers all-in-one protection from heartworm disease, roundworm ticks, fleas, and hookworms. This combo medication builds on the proven success of Simparica (sarolaner) Chewables and demonstrates Zoetis' commitment to parasiticide innovation.
Global Anthelmintics Market Scope
The anthelmintics market is segmented on the basis of drug class, target pathogen, drugs, application, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Benzimidazoles
- Piperazine
Target Pathogen
- Ancylostoma Duodenale
- Ascaris Lumbricoides
- Enterobius Vermicularis
- Trichuris Trichiura
Drugs
- Miltefosine
- Thiabendazole
- Praziquantel
- Mebendazole
- Albendazole
- Pyrantel
- Ivermectin
- Others
Application
- Angiostrongylosis
- Ascariasis
- Capillariasis
- Echinococcus
- Gnathostomiasis
- Liver Fluke
- Moniliformis Infection
- Trichostrongylosis
- Enterobiasis
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Anthelmintics Market Regional Analysis/Insights
The anthelmintics market is analysed and market size insights and trends are provided by country, drug class, target pathogen, drugs, application, route of administration, end-users and distribution channel as referenced above.
The countries covered in the anthelmintics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the anthelmintics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing prevalence of prevalence of helminth infections and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, growing focus of major key players on novel technology will further propel the market's growth rate in this region.
Asia-Pacific is expected to be the fastest growing region during the forecast period of 2022-2029 due to surging number of geriatric population in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Anthelmintics Market Share Analysis
The anthelmintics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anthelmintics market.
Some of the major players operating in the anthelmintics market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Merck & Co., Inc. (US)
- Allergan (Ireland)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Cipla Inc. (US)
- Amneal Pharmaceuticals LLC. (US)
- Merck KGaA (Germany)
- Mankind Pharma (India)
- Zydus Cadila (India)
- GALDERMA (Switzerland)
- Zoetis (US)
- Boehringer Ingelheim International GmbH. (Germany)
SKU-